GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch'
LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event organized by Elsevier Business Intelligence and Windhover Conferences taking place in Boston from November 2-4, 2010, where GENFIT will be presenting its latest scientific achievements.
"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, vice president, content, for Elsevier Business Intelligence's publications. "Many of our past winners have gone on to do big deals, and we expect the same from this year's companies."
The Windhover conference annually elects 10 biopharmaceutical companies with high-value assets for partnership in six specific therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, inflammatory/autoimmune and a category including ophthalmology, orphan diseases, and women's health.
Dr. Dean W. Hum, chief scientific officer of GENFIT, added,"Being a well recognized company in the U.S. in our specific therapeutic area is a great honor for us. We will present our most advanced drug candidate in the field of diabetes, GFT505, and our specific and innovative approach to the prevention and treatment of cardiometabolic diseases. This will be illustrated by the presentation of other internal research programs, in particular those dedicated to the discovery of early biomarkers and those dealing with the connection between circadian cycle dysregulation and metabolic diseases."
About Windhover:Windhover Information Inc, an Elsevier company, has